Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Qiuting Zhang, Huimei Yi, Hui Yao, Lu Lu, Guangchun He, Mi Wu, Chanjuan Zheng, Ying Li, Sisi Chen, Lewei Li, Hongyuan Yu, Guifei Li, Xiaojun Tao, Shujun Fu, Xiyun Deng
Summary: Artemisinin derivatives such as artemisinin and dihydroartemisinin have shown anti-proliferative effects on non-small cell lung cancer (NSCLC) cells by inducing apoptosis and ferroptosis. These findings suggest the potential application of artemisinin derivatives as novel therapeutic drugs for NSCLC.
Article
Oncology
Argyro Roumeliotou, Evangelia Pantazaka, Anastasia Xagara, Foteinos-Ioannis Dimitrakopoulos, Angelos Koutras, Athina Christopoulou, Theodoros Kourelis, Nada H. Aljarba, Saad Alkahtani, Filippos Koinis, Athanasios Kotsakis, Galatea Kallergi
Summary: Studies have shown that JUNB and CXCR4 play important roles in tumor progression and metastasis in various cancer types, including lung cancer. In this study, the expression of JUNB and CXCR4 in circulating tumor cells (CTCs) of lung cancer patients was investigated, and their clinical significance was determined. The results showed that both JUNB and CXCR4 were overexpressed in CTCs from lung cancer patients and were associated with worse survival, indicating that they could be important prognostic biomarkers for lung cancer.
Article
Biochemistry & Molecular Biology
Jessica D. Silva, Joana Marques, Ines P. Santos, Ana L. M. Batista de Carvalho, Clara B. Martins, Raquel C. Laginha, Luis A. E. Batista de Carvalho, Maria Paula M. Marques
Summary: A dinuclear Pt(II) complex with putrescine as bridging polyamine ligand was synthesized and evaluated for its potential anticancer activity against a human non-small cell lung cancer line, as well as non-cancer cells. In vitro cytotoxicity assays, microFTIR, and microRaman spectroscopies were used to assess the effect of the complex. The complex showed a major impact on cellular proteins and lipids in cancer cells, while exhibiting lower toxicity towards non-malignant cells.
Article
Biochemistry & Molecular Biology
Nicole L. Stott Bond, Didier Dreau, Ian Marriott, Jeanette M. Bennett, Michael J. Turner, Susan T. Arthur, Joseph S. Marino
Summary: The study found that metformin treatment did not significantly reduce NSCLC tumor burden in mouse models, nor did it have significant effects on key tumor cell division and inflammation markers or improve skeletal muscle health. Further research is needed to explore combination treatments with metformin as a potential supportive drug rather than a monotherapy to mitigate cancer progression.
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Plant Sciences
Le Kang, Ming-san Miao, Ya-gang Song, Xiao-yan Fang, Jin Zhang, Ya-nan Zhang, Jin-xin Miao
Summary: The study aimed to elucidate the anti-tumor effects of dandelion in vitro and in vivo, as well as assess its effects on immune function in lung cancer patients. The results showed that total flavonoids from Taraxacum mongolicum Hand.-Mazz. had inhibitory effects on lung cancer, potentially by improving the host's immune response.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Oncology
Wei Guo, Qilin Huai, Bolun Zhou, Lei Guo, Li Sun, Xuemin Xue, Fengwei Tan, Qi Xue, Shugeng Gao, Jie He
Summary: This study investigated the role of CXCR4 in predicting immunotherapy response and prognosis in non-small cell lung cancer (NSCLC). The results showed that high CXCR4 expression was associated with poor prognosis and a higher response rate to immunotherapy in NSCLC patients. The study also identified immune prognostic signatures based on CXCR4-related immunomodulators, which showed good performance in predicting patient prognosis in NSCLC.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Medicine, Research & Experimental
Qi Yang, Pei Xu, Qingtao Liu, Fengqing Hu, Xiao Xie, Lianyong Jiang, Rui Bi, Lei Wang, Fangbao Ding, Haibo Xiao
Summary: This study found that DDX1 is overexpressed in non-small cell lung cancer (NSCLC). Depleting DDX1 increased the sensitivity of NSCLC cells to the chemotherapy drug cisplatin, increased cell apoptosis, and inhibited cell migration and invasion. Furthermore, DDX1 bound to ADAR1 and increased ADAR1 protein expression. The results suggest that DDX1 plays an important role in the development and progression of NSCLC and may serve as a therapeutic target in NSCLC patients.
Review
Oncology
Jordi Remon, Benjamin Lacas, Roy Herbst, Martin Reck, Edward B. Garon, Giorgio V. Scagliotti, Rodryg Ramlau, Nasser Hanna, Johan Vansteenkiste, Kiyotaka Yoh, Harry J. M. Groen, John V. Heymach, Sumithra J. Mandrekar, Isamu Okamoto, Joel W. Neal, Rebecca S. Heist, David Planchard, Jean-Pierre Pignon, Benjamin Besse
Summary: This study validates the efficacy of combining angiogenesis inhibitors with second-line treatment in advanced non-small cell lung cancer (NSCLC) patients, showing significant improvements in overall survival and progression-free survival, particularly in younger patients and those who started the first-line therapy more recently.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Giuseppe Giaccone, Yongfeng He
Summary: Lung cancer is the leading cause of cancer related death, with two major histological subtypes, NSCLC and SCLC. Transformation from NSCLC to SCLC can cause treatment resistance, potentially due to therapy-induced changes or clonal selection. This article discusses the potential mechanisms, cell of origin, and genomic alterations in both de novo and transformed SCLC, as well as treatment options including chemotherapy, radiotherapy, TKIs, immunotherapy, and antiangiogenic agents.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Health Care Sciences & Services
Eva Obermayr, Nina Koppensteiner, Nicole Heinzl, Eva Schuster, Barbara Holzer, Hannah Fabikan, Christoph Weinlinger, Oliver Illini, Maximilian Hochmair, Robert Zeillinger
Summary: This study highlighted the importance of molecular characterization of circulating tumor cells (CTCs) in NSCLC patients. The analysis found that cancer stem cell-related transcripts were significantly associated with overall survival at both primary diagnosis and disease progression.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Beatrice Aramini, Valentina Masciale, Anna Valeria Samarelli, Alessandra Dubini, Michele Gaudio, Franco Stella, Uliano Morandi, Massimo Dominici, Sara De Biasi, Lara Gibellini, Andrea Cossarizza
Summary: Lung cancer, especially non-small cell lung cancer (NSCLC), is a major global health concern with high mortality rates. Despite the introduction of new therapies, this disease remains difficult to cure and control. Advancements in single-cell technologies have allowed researchers to better understand the characteristics and functions of immune cells in the tumor microenvironment (TME), leading to the discovery of predictive biomarkers and the development of new therapeutic strategies.
FRONTIERS IN IMMUNOLOGY
(2022)
